Business Wire

Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-19

Share

A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms.

The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures.

The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days.

Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polyphenols when attached to viral protein, mechanically inhibit the workings of the protein, and thus stop the virus from entering the cell. The rest of the 84 patients remained in the control group and were not given the ViroStop solution. Each patient’s symptoms were checked every two days for 12 days.

At the end of the study the level of viral shedding was checked by PCR tests. Those patients who had used the ViroStop spray from the first day after testing positive, showed an almost 60% reduction in viral shedding on day 12, compared to the control group. The study showed that the severity of respiratory clinical symptoms was also reduced in those who used ViroStop spray.

A reduction was also noted in gastrointestinal symptoms compared to the control group. Recent research has shown that a key factor in the spread of the virus is its ability to also multiply in the gastrointestinal tract.

Dr István Jankovics, whose team ran the study commented, “The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response.”

ViroStop is a non-prescription treatment, made from natural ingredients and can be taken safely by children as young as three. Furthermore, at the time of the study, at least three variants of the virus were present in Hungary, so it is reasonable to assume that the solution and the action of polyphenols is effective against all known mutations of Covid-19.

Issued on behalf of:

Herb-Pharma AG
Waldmannstrasse 6,
8001 Zurich, Switzerland

Company email: home@herb-pharma.com
For more information visit: https://www.virostop.info/
Company website: https://www.fytofontana.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries:
virostop@contextpr.co.uk
+44(0)300 124 6100

Eleanor Smith /  Eleanor.smith@contextpr.co.uk

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vantage Data Centers Expands EMEA Portfolio with First Dublin Campus Featuring Next-Generation Energy Solution24.4.2024 12:00:00 CEST | Press release

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into the Irish market with the development of a multi-phase data center campus (DUB1). The company will invest more than €1 billion over multiple phases to support the construction and delivery of the campus in one of the largest data center markets in Europe. The first two phases consist of 52MW of IT capacity, with the first phase expected to be operational in late 2024. Upon completion, DUB1 will mark Vantage’s 14th EMEA campus in a growing regional portfolio that spans seven countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424930079/en/ Vantage Data Centers’ flagship Dublin campus will include 52MW of IT capacity to enable next-generation applications and digital transformation. (Graphic: Business Wire) The company’s flagship Ireland campus will be located approximately nine miles (15 kilometers) f

The Missing Piece - TUC s.r.l presents TUC.tiny: the key to access New Mobility24.4.2024 09:35:00 CEST | Press release

TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tiny™. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries worldwide. A small jewel based on TUC's three technological pillars, mechanical structuring, electronic management and data exchange, designed to also interface with consumer electronics thanks to the integration of USB Type-C technology. TUC.tiny™ becomes the USB of Mobility, a solution that aims to reinvent the interaction between users and vehicles bringing together mobility and everyday life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424672317/en/ TUC dashboard (Photo: Business Wire) A real blank canvas, which can be transformed and customized countless times thanks to TUC.tiny™ and TUC.technology™, flexibly adapting to every need and preference. With TUC's innovative patente

Digital Health Leaders Meet at HIMSS24 Europe to Deliver Solutions to Tomorrow’s Healthcare Challenges24.4.2024 09:03:00 CEST | Press release

To address Europe’s most pressing healthcare challenges, Europe's longest-running, most influential digital health conference returns in 2024, bringing together innovators to shape tomorrow’s healthcare. The HIMSS24 European Health Conference & Exhibition will occur from 29-31 May at the Centro Congressi Roma La Nuvola in Rome, Italy. The conference will be the epicenter for pan-European collaborations and innovation, featuring thought leaders and healthcare professionals working together to create the best technology solutions across the digital health landscape. HIMSS24 Europe will feature programming focused on major global health challenges. Experts will lead discussions on how Europe uses data analytics, artificial intelligence, cybersecurity, and other cutting-edge technologies to address universal issues like health equity, patient privacy, access to care, workforce burnout, staffing shortages, and climate change. Registration is open for HIMSS24 Europe, and interested journalis

Kalray Joins Arm Total Design, Extending Collaboration With Arm on Accelerated AI Processing24.4.2024 09:01:00 CEST | Press release

Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge, announced that it has extended its collaboration with Arm by joining Arm Total Design. Through a deeper connection to industry leaders who are leveraging Arm® Neoverse™ Compute Subsystems (CSS), Kalray can help more companies integrate its unique AI and data acceleration technology and help Arm ecosystem partners commercialize AI-based solutions in a fraction of the time and cost usually needed. Arm Total Design helps accelerate and simplify the delivery of custom silicon based on Arm Neoverse CSS and has grown to more than 20 partners, including the top three leading foundries, ASIC design houses, IP vendors, EDA tool providers, and firmware developers who are driving leading-edge innovation. Kalray is already working to integrate Arm Coherent Mesh Network (CMN) technology to help easily connect Kalray’s advanced AI and data processing

Suzano Ventures invests up to US$5 million into Bioform Technologies to further develop bio-based plastic alternatives24.4.2024 09:01:00 CEST | Press release

Suzano Ventures, the corporate venture capital arm of Suzano, the world’s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company’s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector. Bioform’s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano’s wood pulp fibre as a key input. Bioform’s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye